MyFinsight
Home
Blog
About
Cash and cash
equivalents
$13,269K
(-3.65%↓ Y/Y)
Prepaid expenses and
other current assets
$1,390K
(-16.06%↓ Y/Y)
Total current assets
$14,659K
(-4.98%↓ Y/Y)
Other
$167K
(-4.57%↓ Y/Y)
Total assets
$14,826K
(-4.97%↓ Y/Y)
Accumulated deficit
-$446,788K
(-6.69%↓ Y/Y)
Total liabilities,
redeemable convertible...
$14,826K
(-4.97%↓ Y/Y)
Total stockholders
deficit
-$138,575K
(-16.56%↓ Y/Y)
Additional paid-in capital
$307,667K
(2.79%↑ Y/Y)
Series a 12 convertible
preferred stock 1,742,500...
$480K
(-2.04%↓ Y/Y)
Common stock, 0.001 par
value 150,000,000...
$66K
(4.76%↑ Y/Y)
Total liabilities
$151,678K
(14.24%↑ Y/Y)
Series c 6 super
dividend redeemable...
$1,723K
(0.00%↑ Y/Y)
Total current
liabilities
$151,619K
(1307.27%↑ Y/Y)
Other
$59K
Borrowing and accrued
interest under...
$104,659K
Convertible notes payable
and accrued...
$33,043K
Derivative liabilities
(note 5)
$6,135K
Accrued expenses
$3,993K
(-17.60%↓ Y/Y)
Accounts payable
$3,727K
(-36.45%↓ Y/Y)
Accrued dividends
payable
$62K
(-1.59%↓ Y/Y)
Back
Back
Balance Sheet
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)
source: myfinsight.com